Arrowhead Pharma (ARWR)

$42.31 +2.02 (5.01%)
Market Cap 5.57B
Revenue (ttm) 3.55M
Net Income (ttm) -599.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -16,887.04%
Debt to Equity Ratio 0.46
Volume 2,300,900
Avg Vol 2,340,996
Day's Range N/A - N/A
Shares Out 138.26M
Stochastic %K 85%
Beta 1.13
Analysts Strong Sell
Price Target $45.15

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitryp...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
johnnygogogo
johnnygogogo Oct. 31 at 3:17 PM
$ARWR maybe if we say “buyout” three times it’s like conjuring Beetlejuice for the algos.
0 · Reply
simonsp
simonsp Oct. 31 at 2:57 PM
$ARWR BO talks are always an exercise in futility- but given all of the irons in the fire between Ploz, Dimer, Obesity candidates, Fazirsiran, CNS, Lung -20B (150PPS) is the only figure that would warrant examination at this juncture. If we get approval on all high triglycerides and dominate that market we eat ALNY's lunch for breakfast, and bolt on RNAi juggernaut is a 50B MC enterprise. IMHO.
1 · Reply
mdunbar
mdunbar Oct. 31 at 2:05 PM
$ARWR $40 is gone. Next stop is $60 but it won’t be a smooth ride for sure. Arwr is moving like a stock with a pending buyout. Buyout or not this is a good stock to hold at least for a year.
0 · Reply
Quantumup
Quantumup Oct. 31 at 1:02 PM
Clear Street y'day (MoC)🏁 $KRRO Buy-$93 $ARWR $TAK $WVE $MREO AZN SNY BEAM VRTX CRSP Clear Street said in its initiation report:
0 · Reply
skeezbag
skeezbag Oct. 31 at 12:03 PM
$ARWR name another stock that has this much short volume consistently every fucking day for years
0 · Reply
FactsPlease99
FactsPlease99 Oct. 31 at 11:37 AM
$ARWR added done in mid $30 s to what I already owned. The uptrend was very strong. $42 now. Would love to see it taken out at $90+
0 · Reply
Food4Thought
Food4Thought Oct. 31 at 2:53 AM
$ARWR All eyes about to be on ARWR.
0 · Reply
Pantherfan7979
Pantherfan7979 Oct. 30 at 7:02 PM
$ARWR still not to late.
1 · Reply
diegosan21
diegosan21 Oct. 30 at 4:38 PM
$ARWR glad I bougth my $SRPT sister's shares Yesterday
0 · Reply
MaverikIT
MaverikIT Oct. 30 at 4:30 PM
$ARWR - good 3mth$
0 · Reply
Latest News on ARWR
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Oct 28, 2025, 4:30 PM EDT - 2 days ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Oct 21, 2025, 7:30 AM EDT - 10 days ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Oct 7, 2025, 7:30 AM EDT - 24 days ago

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 4 weeks ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ASMB ATRA CORT

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Sep 11, 2025, 7:30 AM EDT - 7 weeks ago

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 2:55 PM EDT - 7 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Sep 10, 2025, 7:30 AM EDT - 7 weeks ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 1:42 PM EDT - 7 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:35 PM EDT - 7 weeks ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Sep 3, 2025, 4:00 PM EDT - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Citi's 2025 Biopharma Back To School Conference (Transcript)

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Sep 3, 2025, 1:15 PM EDT - 2 months ago

Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

Sep 2, 2025, 8:13 AM EDT - 2 months ago

Arrowhead and Novartis agree up to $2 billion deal for license to neuromuscular therapy

NVS

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Sep 2, 2025, 7:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Aug 27, 2025, 7:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Aug 13, 2025, 4:10 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Aug 8, 2025, 8:48 PM EDT - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Aug 7, 2025, 4:01 PM EDT - 3 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Aug 1, 2025, 6:30 AM EDT - 3 months ago

Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

Jul 28, 2025, 7:30 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

SRPT

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

Jul 23, 2025, 8:00 AM EDT - 3 months ago

Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Jul 22, 2025, 1:30 PM EDT - 3 months ago

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

SRPT

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Jul 21, 2025, 4:01 PM EDT - 3 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jul 8, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jun 23, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 4, 2025, 8:02 AM EDT - 5 months ago

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Jun 2, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 29, 2025, 7:30 AM EDT - 5 months ago

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

May 12, 2025, 9:56 PM EDT - 6 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 12, 2025, 4:01 PM EDT - 6 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

May 7, 2025, 7:30 AM EDT - 6 months ago

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Apr 30, 2025, 4:01 PM EDT - 6 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Apr 15, 2025, 4:00 PM EDT - 7 months ago

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Arrowhead Pharmaceuticals Is Finally Arriving

Mar 21, 2025, 5:56 PM EDT - 7 months ago

Arrowhead Pharmaceuticals Is Finally Arriving

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Mar 10, 2025, 7:30 AM EDT - 8 months ago

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Mar 6, 2025, 8:45 AM EST - 8 months ago

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Feb 28, 2025, 9:00 AM EST - 8 months ago

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Feb 25, 2025, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Feb 19, 2025, 11:53 AM EST - 9 months ago

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 9 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

AZN BHVN KROS LLY NVO REGN SRRK

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 9 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

AUB CRK CYTK EXE KRYS MARA MP

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Feb 10, 2025, 9:35 PM EST - 9 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Feb 10, 2025, 4:01 PM EST - 9 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Feb 10, 2025, 8:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

SRPT

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

Jan 22, 2025, 5:54 PM EST - 10 months ago

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

GWRE

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Jan 22, 2025, 4:00 PM EST - 10 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Jan 17, 2025, 4:30 PM EST - 10 months ago

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Dec 23, 2024, 7:30 AM EST - 11 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Dec 11, 2024, 7:30 AM EST - 11 months ago

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Dec 3, 2024, 7:30 AM EST - 11 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Dec 2, 2024, 7:30 AM EST - 11 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

johnnygogogo
johnnygogogo Oct. 31 at 3:17 PM
$ARWR maybe if we say “buyout” three times it’s like conjuring Beetlejuice for the algos.
0 · Reply
simonsp
simonsp Oct. 31 at 2:57 PM
$ARWR BO talks are always an exercise in futility- but given all of the irons in the fire between Ploz, Dimer, Obesity candidates, Fazirsiran, CNS, Lung -20B (150PPS) is the only figure that would warrant examination at this juncture. If we get approval on all high triglycerides and dominate that market we eat ALNY's lunch for breakfast, and bolt on RNAi juggernaut is a 50B MC enterprise. IMHO.
1 · Reply
mdunbar
mdunbar Oct. 31 at 2:05 PM
$ARWR $40 is gone. Next stop is $60 but it won’t be a smooth ride for sure. Arwr is moving like a stock with a pending buyout. Buyout or not this is a good stock to hold at least for a year.
0 · Reply
Quantumup
Quantumup Oct. 31 at 1:02 PM
Clear Street y'day (MoC)🏁 $KRRO Buy-$93 $ARWR $TAK $WVE $MREO AZN SNY BEAM VRTX CRSP Clear Street said in its initiation report:
0 · Reply
skeezbag
skeezbag Oct. 31 at 12:03 PM
$ARWR name another stock that has this much short volume consistently every fucking day for years
0 · Reply
FactsPlease99
FactsPlease99 Oct. 31 at 11:37 AM
$ARWR added done in mid $30 s to what I already owned. The uptrend was very strong. $42 now. Would love to see it taken out at $90+
0 · Reply
Food4Thought
Food4Thought Oct. 31 at 2:53 AM
$ARWR All eyes about to be on ARWR.
0 · Reply
Pantherfan7979
Pantherfan7979 Oct. 30 at 7:02 PM
$ARWR still not to late.
1 · Reply
diegosan21
diegosan21 Oct. 30 at 4:38 PM
$ARWR glad I bougth my $SRPT sister's shares Yesterday
0 · Reply
MaverikIT
MaverikIT Oct. 30 at 4:30 PM
$ARWR - good 3mth$
0 · Reply
Pantherfan7979
Pantherfan7979 Oct. 30 at 4:23 PM
$ARWR
0 · Reply
SBL71
SBL71 Oct. 30 at 4:13 PM
$ARWR
0 · Reply
JCLuckman
JCLuckman Oct. 30 at 4:06 PM
$ARWR FOMO 🔥
0 · Reply
1ightningscalps
1ightningscalps Oct. 30 at 4:02 PM
1ightning® Options Trade Alert (Actionable) | Buy $ARWR Nov 21 $45 Call | Enter: $1.20 Exit: $2.29 | Profit: 91.21% ROI | https://1ightning.com
0 · Reply
StockingStuffer2832
StockingStuffer2832 Oct. 30 at 3:27 PM
$ARWR we got a runner
0 · Reply
Gkal39
Gkal39 Oct. 30 at 3:21 PM
$ARWR glad I added in the teens to my core position. As always.🐻🔨
0 · Reply
CDMO
CDMO Oct. 30 at 3:10 PM
$ARWR incredibly strong
0 · Reply
JCLuckman
JCLuckman Oct. 30 at 2:15 PM
$ARWR
0 · Reply
Stock81
Stock81 Oct. 30 at 2:03 PM
$ARWR 84 new employees, creating a sales team?
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 30 at 10:30 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $ARWR Current Share Price: $39.03 Contracts: $ARWR January 15, 2027 $40 Calls Scale in: $10.08- $12.32 Scale out: $15.68-$20.16 Can Easily Capture: 60% ROI Blended DTE: 443 Days | Join Elites here: https://liquidtheta.com
0 · Reply
SBL71
SBL71 Oct. 29 at 5:05 PM
$ARWR it's taken since Dec 2022 to get back to $40... no regrets, just taking a look at some Hx. See if we can get back to $80 by the turn of calendar.
0 · Reply
SBL71
SBL71 Oct. 29 at 4:28 PM
$ARWR hey there it is $40
1 · Reply